In the present study, our findings demonstrated that the measurement of serum exosomal PD-L1 as a quantitative complementary factor together with tumor PD-L1 status might help predict anti-PD-1 response and assess clinical outcomes in patients with NSCLC. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.